Latham & Watkins Advises Lux Health Tech Acquisition Corp. in US$300 Million Initial Public Offering

A multidisciplinary team advised the special purpose acquisition company in the transaction.

October 26, 2020

Lux Health Tech Acquisition Corp. (the Company) has announced the pricing of its initial public offering of 30,000,000 units at a price of US$10.00 per unit. The units will be listed on the Nasdaq Stock Market, LLC (Nasdaq) and will trade under the ticker symbol “LUXAU”. Each unit issued in the offering consists of one share of the Company’s Class A common stock and one-third of one warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at an exercise price of US$11.50 per share. After the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “LUXA” and “LUXAW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

Latham & Watkins LLP represents Lux Health Tech Acquisition Corp. in the offering with a corporate deal team led by Houston partner Ryan Maierson, with Houston associates Ryan Lynch, Madeleine Neet, Paul Robe, and Trevor Bossi and Washington, D.C. associate Ashlyn Royall. Advice was also provided on tax matters by Houston partners Tim Fenn and Bryant Lee, with Houston associate Chelsea Munoz-Patchen; and on investment funds matters by Houston partner Ivana Rouse, with Houston associate Cassy Romano.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.